Matrix Metalloproteinase-9 as a Prognostic Factor in Gastric Cancer: A Meta-Analysis

  • Zhang, Qiong-Wen (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Liu, Lei (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Chen, Ru (Department of Oncology, The People's Hospital of Xinjiang Uygur Autonomous Region) ;
  • Wei, Yu-Quan (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Li, Ping (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Shi, Hua-Shan (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Zhao, Yu-Wei (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University)
  • Published : 2012.06.30


Background: Matrix metalloproteinase-9 (MMP-9) is associated with disruption of basement membranes of blood vessels and promotion of metastasis through the lymphatics. However, its prognostic value for survival in patients with gastric cancer remains controversial. Method: We therefore conducted a meta-analysis of the published literature in order to clarify the impact of MMP-9. Clinical studies were selected for further analysis if they provided an independent assessment of MMP-9 in gastric cancer and reported analysis of survival data according to MMP-9 expression. Results: A total of 11 studies, covering 1700 patients, were included for meta-analysis. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive MMP-9 expression had an impact on overall survival: 1.25 (95% confidence interval 1.11-1.40) in all eligible studies; 1.13 (1.06-1.20) in 8 studies detecting MMP-9 by immunohistochemistry; 1.36 (1.12-1.65) in 7 studies from Asia. Only one study for DFS showed a significant impact on disease free survival (HR 1.73, 95%CI 1.27-2.34). Conclusions: Our findings suggested that MMP-9 protein expression might be a factor for a poor prognosis in patients with gastric cancer. However, the association was rather weak, so that more prospective studies should further explore the prognostic impact of MMP-9 mRNA and correlations between MMP-9 and clinicopathological characteristics.


  1. Allgayer H, Heiss MM, Schildberg FW (1997). Prognostic factors in gastric cancer. Br J Surg, 84, 1651-64.
  2. Altman DG (2001). Systematic reviews of evaluations of prognostic variables. BMJ, 323, 224-8.
  3. Begg C, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  4. Brenner H, Rothenbacher D, Arndt V (2009). Epidemiology of stomach cancer.Cancer Epidemiology, 472, 467-77.
  5. Chu D, Zhang Z, Li Y, et al (2010). Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer, 129, 887-95.
  6. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
  7. Czyzewska J, Guzinska-Ustymowicz K, Kemona A, et al (2008). The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol, 46, 57-64.
  8. De Mingo M, Moran A, Sanchez-Pernaute A, et al (2007). Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology, 54, 315-9.
  9. Earleywine M (1993). The file drawer problem in the meta analysis of the subjective responses to alcohol. Am J Psychiatry, 150, 1435-6.
  10. Egger M, Smith GD, Schneider M, et al (1977). Bias in metaanalysis detected by a simple, graphical test. BMJ, 629-34.
  11. Egger M, Zellweger-Zahner T, Schneider M, et al (1997). Language bias in randomized controlled trials published in English and German. Lancet, 350, 326-9.
  12. Ferlay J, Parkin DM, Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46, 765-81.
  13. Harrison JD, Fielding JW (1995). Prognostic factors for gastric cancer influencing clinical practice. World J Surg, 19, 496- 500.
  14. Hayes DF, Isaacs C, Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland BiolNeoplasia, 6, 375-92.
  15. Jackson C (2002).Matrix metalloproteinases and angiogenesis. Current Opinion in Nephrology and Hypertension, 11, 295-9.
  16. Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  17. Johansson N, Ahonen M, Kahari VM (2000). Matrix metalloproteinases in tumor invasion. CMLS Cell Mol Life Sci, 57, 5-15.
  18. Kim BS, Cho SW, Min SK, et al (2011). Differences in prognostic factors between early and advanced gastric cancer. Hepatogastroenterology, 58, 1032-40.
  19. Kyzas PA, Cunha IW, Ioannidis JP (2005). Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res, 11, 1434-40.
  20. Li L, Zhang S, Lin H, et al (2002). Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng, 21, 305-310.
  21. Mantel N, Haenszel W (1959).Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  22. McCawley LJ, Matrisian LM (2000). Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today, 6, 149-56.
  23. Miao R, Li L, Wang Y, et al (2007). Expression and clinical significance of matrix metalloproteinase in gastric stromal tumor. Zhonghua Wai Ke Za Zhi, 45, 1196-8.
  24. Mrena J, Wiksten J-P, Nordling S, et al (2006). MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J ClinPathol, 59, 618-23.
  25. Nabeshima K, Inoue T, Shimao Y, et al (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52, 255-64.
  26. Park HI, Ni J, Gerkema FE, et al (2000). Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem, 275, 20540-4.
  27. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  28. Peng C, Liu X, Liu X, et al (2010). Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J Transl Med, 8, 101.
  29. Reinmuth N, Parikh AA, Ahmad SA, et al (2003). Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech, 60, 199-207.
  30. Ren T, Wu J, Zhou Y, et al (2010). c-Jun and MMP-9 protein expression and the biologic action in gastric carcinoma. Chin J Clin Oncol, 37, 19-22.
  31. Rundhaug JE (2005). Matrix metalloproteinases and angiogenesis. J Cell Mol Med, 9, 267-85.
  32. Seo YS, Park JJ, Kim JH, et al (2007). Usefulness of MMP- 9/ TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci, 52, 753-9.
  33. Seshadri RA, Jayanand SB, Ranganathan R (2011). Prognostic factors in patients with node-negative gastric cancer: an Indian experience. World J SurgOncol, 9, 48
  34. Sier C, Kubben F, Ganesh S, et al (1996). Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer, 74, 413-7.
  35. Simon R, Altman DG (2001). Statistical aspects of prognostic factor studies in oncology. Br J Cancer, 69, 979-85.
  36. Stetler-Stevenson WG (2001).The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Cancer Metastasis: Biological and Clinical Aspects, 10, 383-92.
  37. Stewart LA, Parmar MK (1993). Meta-analysis of the literature or of individual patient data: is there a difference? Lancet, 341, 418-22.
  38. Tang Y, Zhu J, Chen L, et al (2008). Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin Cancer Res, 14, 2870-7.
  39. Tong J, Sun X, Cheng H, et al (2011). Expression of p16 in nonsmall cell lung cancer and its prognostic significance: a metaanalysis of published literatures. Lung Cancer, 74, 155-63.
  40. Ueda Y, Imai K, Tsuchiya H, et al (1996). Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol, 148, 611-22.
  41. Vidal O, Soriano-Izquierdo A, Pera M, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curative resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J GastrointestSurg, 12, 1005-14.
  42. Wang J, Tian X, Wang S, et al (2005). Correlation between expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and angiogenesis in gastric cancer. Chin J Cancer Res, 17, 283-7.
  43. Yang L. Incidence and mortality of gastric cancer in China (2006). World J Gastroenterol, 12, 17-20.
  44. Yang Q, Ye Z, Zhang J, et al (2010). Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anatomical Record, 293, 2012-9.
  45. Yasui W, Oue N, Aung PP, et al (2005). Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer, 8, 86-94.
  46. Zhang S, Li L, Lin J, et al (2003). Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol, 9, 899-904.
  47. Zhao D, Xu H, Li K, et al (2010). Prognostic factors for patients after curative resection for proximal gastric cancer. J Huazhong Univ Sci Technolog Med Sci, 30, 530-5.
  48. Zhao ZS, Wang YY, Ye ZY, et al (2009). Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res, 15, 589-96.
  49. Zhao Z, Zhou J, Yao G, et al (2005). Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol, 11, 3227-33.
  50. Zheng H, Takahashi H, Murai Y, et al (2006). Upregulated EMMPRIN/CD 147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer, 95, 1371-8.
  51. Zhong S, Wang Y, Ye Z, et al (2009). Prognostic value of tumorrelated molecular expression in gastric carcinoma. Pathol Oncol Res, 15, 589-96.
  52. Zhong S, Yao G, Ru G, et al (2005). Relationship between bFGF mRNA and MMP-9 mRNA expression in gastric carcinoma and their clinicopathological features as well as patients survival. Zhong Hua Wai Ke Za Zhi, 43, 169-73.

Cited by

  1. Prognostic Value of Matrix Metalloproteinase 9 Expression in Breast Cancer Patients: A Meta-analysis vol.14, pp.3, 2013,
  2. Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma vol.2013, pp.1537-744X, 2013,
  3. Prognostic value of HIF-1α expression in patients with gastric cancer vol.40, pp.11, 2013,
  4. Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC) vol.15, pp.12, 2014,
  5. Prognostic Significance of Beta-Catenin Expression in Patients with Esophageal Carcinoma: a Meta-analysis vol.15, pp.15, 2014,
  6. Cinobufacin Suppresses Cell Proliferation via miR-494 in BGC-823 Gastric Cancer Cells vol.15, pp.3, 2014,
  7. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma vol.35, pp.6, 2014,
  8. Cyclooxygenase-2 Expression Is Associated with Poor Overall Survival of Patients with Gastric Cancer: A Meta-Analysis vol.59, pp.2, 2014,
  9. Prognostic Significance of Matrix Metalloproteinase-7 in Gastric Cancer Survival: A Meta-Analysis vol.10, pp.4, 2015,
  10. An Overview of Matrix Metalloproteinase 9 Polymorphism and Gastric Cancer Risk vol.16, pp.17, 2015,
  11. Association and Prognostic Significance of the Functional −1562C/T Polymorphism in the Promoter Region of MMP-9 in Turkish Patients with Gastric Cancer vol.21, pp.4, 2015,
  12. Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer vol.3, pp.6, 2015,
  13. Molecular targeted therapy for the treatment of gastric cancer vol.35, pp.1, 2016,
  14. The prognostic value of E-cadherin in gastric cancer: A meta-analysis vol.132, pp.11, 2012,
  15. Expression and function of transforming growth factor-β-activated protein kinase 1 in gastric cancer vol.16, pp.3, 2017,
  16. High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates vol.13, pp.3, 2017,
  17. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma vol.97, pp.44, 2018,
  18. Emerging Therapies in the Management of Advanced-Stage Gastric Cancer vol.9, pp.1663-9812, 2018,